New Generation IGRA in Immunocompromised Individuals — TBnet#54  

Active Tuberculosis Clinical Trial

Official title: Performance of a New Generation IGRA in Immunocompromised Individuals

Status Recruiting

Clinical Trial Summary

Evaluation of a new ELISA based interferon-gamma release assay (QuantiFERON TB plus In-tube test) in immunocompromized patients

Clinical Trial Description

This study is designed to evaluate the performance of a new ELISA based QuantiFERON-TB plus In-tube test to identify M. tuberculosis specific immune Responses as evidence of latent infection with M. tuberculosis in immunosuppressed populations. Both qualitative and quantitative test results will be related to the level of immunodeficiency and to the presence of risk factors for prior exposure with M. tuberculosis. In addition, patients with active tuberculosis (both immunocompetent and immunocompromised individuals) will be included to evaluate a potential increase in sensitivity in these groups. Immunocompetent individuals with low risk of exposure will be analysed as a proxy to estimate specificity. Finally, this study will be extended to longitudinally assess the predictive value of a positive blood test for progression to active disease. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Active Tuberculosis
• Arthritis, Rheumatoid
• Kidney Failure, Chronic
• Monitoring, Immunologic
• Renal Insufficiency
• Tuberculosis
• Tuberculosis in Chronic Renal Failure
• Tuberculosis in HIV-infected Individuals
• Tuberculosis in Marrow Transplant Recipients
• Tuberculosis in Rheumatoid Arthritis
• Tuberculosis in Solid Organ Transplant Recipients

• NCT number: NCT02639936
• Study type: Observational
• Source: Tuberculosis Network European Trialsgroup
• Contact: Martina Sester, PhD
• Phone: 0049-6841-16
• Email: martina.sester@uks.eu
• Status: Recruiting
• Phase: N/A
• Start date: December 2015
• Completion date: December 2019